Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer Japan has released top-line positive results from a double-blind, placebo-controlled, multicenter, randomized and parallel group Study A0081208 of Lyrica (pregabalin) in patients with fibromyalgia.
Subscribe to our email newsletter
The study investigated the safety and efficacy of Pregabalin (CI-1008) in the treatment of fibromyalgia.
The results of the trial showed reduction in the endpoint mean pain score with pregabalin in comparison to placebo.
The trial involved around 501 patients (251 pregabalin and 250 placebo) in 45 investigative sites in Japan.
Pfizer Japan Development head and vice president Akihisa Harada said they look forward to more fully understanding the potential benefits that Lyrica may bring to fibromyalgia patients in Japan.